We are delighted to welcome Dr Philip Scheltens to his new position as one of the Editors-in-Chief of Alzheimer’s Research & Therapy, joining Dr Douglas Galasko (University of California, San Diego, USA) and Dr Todd Golde (University of Florida, USA). Dr Scheltens is replacing Dr Gordon Wilcock (University of Oxford, UK), who is stepping down from this role after many valuable years of guidance as Editor-in-Chief.
Dr Scheltens is Professor of Cognitive Neurology and Director of the Alzheimer Centre at the VU University Medical Centre in Amsterdam, which he founded in 2000. Dr Scheltens is active in the field of biomarkers and clinical trials, with his main clinical and research interests including Alzheimer’s disease, vascular dementia, frontotemporal dementia, magnetic resonance imaging, PET imaging and biomarkers.
Dr Scheltens commented, “I am excited to join my esteemed colleagues to lead the journal. The field of Alzheimer’s disease is going through a very interesting and exciting phase and the journal is rightly positioned to make some important contributions to this field.”
As a major forum for translational research into Alzheimer’s dementia and other neurodegenerative diseases, Alzheimer’s Research & Therapy is dedicated to publishing international peer-reviewed articles at the forefront of scientific breakthroughs in this field. The journal is affiliated to Alzheimer’s Disease International and the Editors-in-Chief are supported by a world-renowned Editorial Board.
The journal will be receiving its first Thomson Reuters (ISI) Impact Factor next month. In addition to the bibliographic databases that articles published in Alzheimer’s Research & Therapy are currently included, such as CAS, Embase, PubMed, PubMed Central and Scopus, the journal will also be indexed in Science Citation Index Expanded, Journal Citation Reports and Current Contents.
For more information on Alzheimer’s Research & Therapy, or to submit a manuscript, please visit the journal website or contact the Editorial Office. To keep up to date with the latest articles published in the journal, sign up for Article Alerts and follow us on twitter.